



Molecular Mechanisms of Normal and Malignant Hematopoiesis

Guest Editor:

Dr. Myunggon Ko

Department of Biological
Sciences, Ulsan National Institute
of Science and Technology,
Ulsan 44919, Republic of Korea

Deadline for manuscript
submissions:

closed (15 October 2023)

Message from the Guest Editor

For this Special Issue, we invite reviews or original research articles that describe the roles of chromatin modifications and the relevant enzymes that establish, erase, and interpret these epigenetic marks during normal and malignant hematopoiesis. We will also accept articles addressing roles for epigenetic modifiers in the consolidation of inputs from the HSC niche or intracellular metabolism with genetic programs to secure normal HSC self-renewal and differentiation. Topics relevant to the discoveries of novel genetic and epigenetic perturbations, their functional contribution to hematological oncogenesis, and advanced strategies targeting epigenetic modifications for treating hematological malignancies obtained through translational studies are also welcomed.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)